Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11606364rdf:typepubmed:Citationlld:pubmed
pubmed-article:11606364lifeskim:mentionsumls-concept:C0534628lld:lifeskim
pubmed-article:11606364lifeskim:mentionsumls-concept:C0007112lld:lifeskim
pubmed-article:11606364lifeskim:mentionsumls-concept:C0596087lld:lifeskim
pubmed-article:11606364lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:11606364lifeskim:mentionsumls-concept:C1882417lld:lifeskim
pubmed-article:11606364pubmed:issue20lld:pubmed
pubmed-article:11606364pubmed:dateCreated2001-10-18lld:pubmed
pubmed-article:11606364pubmed:abstractTextWe have performed association studies between a novel coding single nucleotide polymorphism (D104N) in endostatin, one of the most potent inhibitors of angiogenesis, and prostate cancer. We observed that heterozygous N104 individuals have a 2.5 times increased chance of developing prostate cancer as compared with homozygous D104 subjects (odds ratio, 2.4; 95% confidence interval, 1.4-4.16). Modeling of the endostatin mutant showed that the N104 protein is stable. These results together with the observation that residue 104 is evolutionary conserved lead us to propose that: (a) the DNA segment containing this residue might contain a novel interaction site to a yet unknown receptor; and (b) the presence of N104 impairs the function of endostatin.lld:pubmed
pubmed-article:11606364pubmed:languageenglld:pubmed
pubmed-article:11606364pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11606364pubmed:citationSubsetIMlld:pubmed
pubmed-article:11606364pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11606364pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11606364pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11606364pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11606364pubmed:statusMEDLINElld:pubmed
pubmed-article:11606364pubmed:monthOctlld:pubmed
pubmed-article:11606364pubmed:issn0008-5472lld:pubmed
pubmed-article:11606364pubmed:authorpubmed-author:SuzukiOOlld:pubmed
pubmed-article:11606364pubmed:authorpubmed-author:Moreira-Filho...lld:pubmed
pubmed-article:11606364pubmed:authorpubmed-author:OlivaGGlld:pubmed
pubmed-article:11606364pubmed:authorpubmed-author:AlvesV AVAlld:pubmed
pubmed-article:11606364pubmed:authorpubmed-author:SimpsonAAlld:pubmed
pubmed-article:11606364pubmed:authorpubmed-author:SoaresFFlld:pubmed
pubmed-article:11606364pubmed:authorpubmed-author:MoreiraE SESlld:pubmed
pubmed-article:11606364pubmed:authorpubmed-author:Passos-BuenoM...lld:pubmed
pubmed-article:11606364pubmed:authorpubmed-author:di LoretoCClld:pubmed
pubmed-article:11606364pubmed:authorpubmed-author:CamargoAAlld:pubmed
pubmed-article:11606364pubmed:authorpubmed-author:IughettiPPlld:pubmed
pubmed-article:11606364pubmed:authorpubmed-author:SertiéA LALlld:pubmed
pubmed-article:11606364pubmed:authorpubmed-author:GodoiP HPHlld:pubmed
pubmed-article:11606364pubmed:authorpubmed-author:ZorickTTlld:pubmed
pubmed-article:11606364pubmed:issnTypePrintlld:pubmed
pubmed-article:11606364pubmed:day15lld:pubmed
pubmed-article:11606364pubmed:volume61lld:pubmed
pubmed-article:11606364pubmed:ownerNLMlld:pubmed
pubmed-article:11606364pubmed:authorsCompleteYlld:pubmed
pubmed-article:11606364pubmed:pagination7375-8lld:pubmed
pubmed-article:11606364pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:meshHeadingpubmed-meshheading:11606364...lld:pubmed
pubmed-article:11606364pubmed:year2001lld:pubmed
pubmed-article:11606364pubmed:articleTitleA polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma.lld:pubmed
pubmed-article:11606364pubmed:affiliationCentro de Estudos do Genoma Humano, Departamento de Biologia, Instituto de Biociências, USP, São Paulo 05508-900, Brasil.lld:pubmed
pubmed-article:11606364pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11606364pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:80781entrezgene:pubmedpubmed-article:11606364lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11606364lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11606364lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11606364lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11606364lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11606364lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11606364lld:pubmed